Compare SCYX & LPSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SCYX | LPSN |
|---|---|---|
| Founded | 1999 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | EDP Services |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 32.6M | 32.3M |
| IPO Year | 2014 | 2000 |
| Metric | SCYX | LPSN |
|---|---|---|
| Price | $0.89 | $2.66 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 1 | 1 |
| Target Price | ★ $3.00 | N/A |
| AVG Volume (30 Days) | ★ 318.1K | 126.2K |
| Earning Date | 03-04-2026 | 03-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 61.36 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $257,000.00 | ★ $249,838,000.00 |
| Revenue This Year | $90.24 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.57 | $0.39 |
| 52 Week High | $1.29 | $7.54 |
| Indicator | SCYX | LPSN |
|---|---|---|
| Relative Strength Index (RSI) | 61.44 | 38.62 |
| Support Level | $0.68 | $2.56 |
| Resistance Level | $1.29 | $3.43 |
| Average True Range (ATR) | 0.06 | 0.19 |
| MACD | 0.01 | -0.02 |
| Stochastic Oscillator | 72.58 | 11.13 |
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.
LivePerson Inc is the enterprise leader in digital customer conversation. The Conversational Cloud, the Company's enterprise-class digital customer conversation platform, is trusted by the world's top brands to accelerate their contact center transformation, orchestrate conversations across all channels, departments, and systems, increase agent productivity, and deliver more personalized, AI-empowered customer experiences. The company has a presence in the United Kingdom, Asia-Pacific, Latin America, and Europe.